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Dual PI3K and Wnt pathway inhibition is a synergistic
combination against triple negative breast cancer
Jeffrey P. Solzak1, Rutuja V. Atale1, Bradley A. Hancock1, Anthony L. Sinn2, Karen E. Pollok2,3, David R. Jones4 and Milan Radovich1
Triple negative breast cancer accounts for 15–20% of all breast cancer cases, but despite its lower incidence, contributes to a
disproportionately higher rate of mortality. As there are currently no Food and Drug Administration-approved targeted agents for
triple negative breast cancer, we embarked on a genomic-guided effort to identify novel targeted modalities. Analyses by our
group and The Cancer Genome Atlas have identiﬁed activation of the PI3K-pathway in the majority of triple negative breast
cancers. As single agent therapy is commonly subject to resistance, we investigated the use of combination therapy against
compensatory pathways. Herein, we demonstrate that pan-PI3K inhibition in triple negative breast cancers results in marked
activation of the Wnt-pathway. Using the combination of two inhibitors currently in clinical trial as single agents, buparlisib(pan-
PI3K) and WNT974(WNT-pathway), we demonstrate signiﬁcant in vitro and in vivo synergy against triple negative breast cancer cell
lines and xenografts. Taken together, these observations provide a strong rationale for testing dual targeting of the PI3K and WNT-
pathways in clinical trials.
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INTRODUCTION
Triple negative breast cancer (TNBC) accounts for 15% of all breast
cancer cases in the United States, and despite its lower incidence,
contributes to a disproportionately higher rate of mortality
compared to other breast cancer subtypes. Because these tumors
lack over-expression of the estrogen, progesterone, and HER-2
receptors (“triple-negative”), these patients do not respond to
targeted therapies that have been successfully used against
tumors that over-express these proteins.1–5 Agents such as
tamoxifen, the aromatase inhibitors, and trastuzumab (Herceptin)
have made major advances in improving survival for hormone-
positive and HER-2 positive breast cancers, but successful targeted
therapies have been absent in TNBC. Treatment options are very
limited to TNBC patients beyond standard chemotherapy.6
Particularly in the curative setting, the drugs that comprise
adjuvant and neoadjuvant chemotherapy for TNBC (anthracy-
clines, cyclophosphamide, taxanes, and platinum) have existed for
decades. Previous attempts to introduce targeted therapies in
TNBC by inhibiting the EGFR and c-KIT receptors have resulted in
negative clinical trials.7–11 More recent attempts to introduce PARP
inhibitors for TNBC have demonstrated some clinical success,
though it may be limited to speciﬁc BRCA1 subpopulations.12–14
Very recent data targeting the androgen receptor (AR) with
enzalutamide in a small subtype of TNBCs that are AR-positive
showed some promising clinical results, but the efﬁcacy is
restricted to a limited subpopulation.15 Recent excitement with
immune therapy has spurred on efforts to test immune
checkpoint therapy in TNBC. The phase Ib JAVELIN trial using
avelumab, an anti-PD-L1 antibody, showed a low overall response
rate of 8.6% in patients with metastatic TNBCs, but the responses
were durable.16 In another phase Ib trial using pembrolizumab in
advanced TNBC, results demonstrated an 18.5% overall response
rate, with a subset also having a long durable response.17 While
targeted therapies are available on trial for niche populations of
TNBCs, a critical need exists to identify novel therapies for the vast
majority of patients with this disease. In an effort to identify novel
targets for TNBC, our group has previously published a
comprehensive transcriptional compendium of 94 TNBCs com-
pared to microdissected normal breast tissue using next-
generation RNA-sequencing.18 Subsequent analyses of this data
using novel network analysis tools, has identiﬁed activation and
over-expression of the PI3K/AKT/mTOR (PI3K) pathway and the
Wnt Pathway. The PI3K pathway is well known for its role in
cellular proliferation and survival,19 and the Wnt pathway is well
known for its role in tissue development.20 Early stage inhibitors of
these two pathways are currently in clinical trials (clinicaltrials.
gov). Buparlisib (a pan-PI3K inhibitor), and WNT974 (a Wnt
pathway inhibitor) were obtained to perform in vitro and in vivo
testing. Herein, we will show that treatment with the combination
of buparlisib and WNT974 is highly synergistic in reducing TNBC
viability. In addition, our data demonstrates that treatment with
buparlisib, induces compensatory expression of Wnt pathway
proteins namely, porcupine (the protein target for WNT974),
whose O-acyltransferase activity is required for Wnt ligand
pamitoylation and secretion.21 These data demonstrate a potential
mode of synergy for these two agents and may provide a viable
therapeutic option for patients with TNBC.
RESULTS
RNA sequencing identiﬁes overexpressed PI3K pathway
RNA sequencing data comparing 94 TNBCs to 20 normal breast
tissues (microdissected ductal epithelium from healthy volunteers)
were analyzed to identify differentially expressed genes, as
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previously described.18 When considering a false discovery rate
(FDR) < 0.05 with a fold change more than ± 2, we identiﬁed 3,197
differentially expressed genes in TNBCs vs. microdissected normal
breast tissue (Supplementary Table 1). To perform drug develop-
ment studies, we employed network and pathway analysis to
identify key targetable pathways using these differentially
expressed genes. From this analysis, we observed over-
expression of the PI3K/AKT/mTOR (PI3K) pathway whose compo-
nents included over- expressed AKT, p21, 4E-BP1, S6 Kinase, and
others (Fig. 1a, b). Congruent with our RNA-seq data, published
analyses from the The Cancer Genome Atlas (TCGA) has also
conﬁrmed genomic activation of this pathway even in TNBC
samples that do not harbor PIK3CA or PTEN mutations.22 To
further illustrate this, we used the cBioPortal database (cbioportal.
org) to mine the TCGA TNBC data, and as shown in Fig. 1c, the
majority of TNBCs harbor a genomic aberration in the canonical
components of the PI3K, AKT, and/or PTEN genes.
Network analysis predicts compensatory Wnt pathway activation
It is well known that single-agent therapy is not always clinically
effective, and resistance is common secondary to the activation of
compensatory pathways.23–25 To this end, we analyzed the RNA-
seq data to identify complementary pathways that could be
targeted using rational combinations. To do this, we performed an
in silico experiment using a new tool called Molecular Activity
Predictor (MAP) analysis [a part of the Ingenuity Pathway Analysis
(IPA) 9.0 package. The MAP tool enables the prediction of
upstream and/or downstream effects of activation or inhibition
of molecules in a network or pathway given a starting set of
neighboring molecules with “known” activity or expression. This
tool leverages the vast literature library present in IPA. As seen in
Supplementary Fig. 1, when buparlisib is added in silico (red color),
it results in certain components of the PI3K pathway to become
inhibited (blue color) including: PIK3CA, PIK3CB, PIK3CD, PIK3CG
and others. The in silico addition of buparlisib (BKM120) also
Fig. 1 a Pathway analysis of RNA-seq data comparing 94 TNBCs vs. 20 normal breast tissues reveals the overexpression of the PI3K/AKT
pathway. Statistical analysis revealed 3,197 genes (FDR< 5%, with a fold change more than ±2) that are differentially expressed between TNBC
and normal (Supplementary Table 1). Signiﬁcant genes were imported into ingenuity pathway analysis, revealing an active PI3K/AKT pathway.
b The gene expression fold-changes and p-values of the differentially expressed components of the PI3K pathway in 1 a. c TCGA analysis using
the cBioPortal database of 139 TNBC patients show that approximately 92% of individuals have an observed genomic aberration within the
PI3K/AKT pathway. In this oncoprint plot, each row represents the stated gene, and each column is an individual patient. Colors representing
each form of aberration are depicted below the plot
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causes certain components of the Wnt pathway to become
activated (orange color) including: Wnt ligands (WNT5, WNT6,
WNT7, etc), frizzled receptors (FZD), beta-catenin (CTNNB1), LRP1/
5/6, and others.
To experimentally conﬁrm the in silico observation of Wnt
pathway induction after PI3K inhibition, we produced preliminary
data treating the TNBC cell line MDA-MB-231 with buparlisib, and
performing RNA-seq before and after treatment. As shown in
Fig. 2a, treatment of MDA-MB-231 cells with buparlisib results in a
signiﬁcant increase in the expression of Wnt pathway genes. In
Fig. 2a, the expression values of a portion of the Wnt pathway
genes are shown, including, porcupine (PORCN), the receptors of
Wnt ligands (FZD proteins), protein tyrosine kinase (PTK7),
lipoprotein receptor-related proteins 4 and 6 (LRP4, LRP6), β-
catenin (CTNNB1), and several WNT ligands (expression values of
the full gene list is in (Supplementary Table 2). Druggable genes of
interest, PORCN and PTK7, were validated through quantitative
polymerase chain reaction (qPCR, Supplementary Fig. 2). Of
particular interest, the gene porcupine (PORCN), is ~8-fold over-
expressed after PI3K inhibition with buparlisib. Porcupine, is a
critical protein involved in Wnt ligand maturation, whose O-
acyltransferase activity is required for Wnt ligand pamitoylation
and secretion.21 More importantly, porcupine is the target of one
of only three drugs currently in clinical trial that target the Wnt
pathway (clinicaltrials.gov). WNT974, is an oral small molecule
inhibitor of porcupine, and recently published data has demon-
strated potent inhibition of its target and signiﬁcant inhibition of
tumor growth in vivo.26
To further conﬁrm the induction of porcupine after buparlisib
treatment, but at the protein level, we performed western blotting
for porcupine and p-AKT before and after treatment with
buparlisib. Across three TNBC cell lines: MDA-MB-231, HCC70,
and HCC1143; treatment with buparlisib resulted in potent
inhibition of phospho-AKT as expected (Fig. 2b). Conversely, we
observed a signiﬁcant increase in porcupine protein expression
after incubation with buparlisib (Fig. 2b). Quantiﬁcation of HCC70
PORCN protein only saw a signiﬁcant increase at 10 × IC50
buparlisib treated (p-value 0.0084), while HCC1143 and MD-MB-
Fig. 2 a RNA expression of Wnt pathway molecules after buparlisib treatment of the TNBC cell line MDA-MB-231. Cells were treated with
buparlisib and RNA-seq (Ampliseq Transcriptome, see methods) was performed on extracted RNA before and after treatment. Genes in the
WNT pathway that were observed to have a change in expression include the protein target of WNT974, porcupine (PORCN), as well as the
Wnt ligands, FZD receptors, PTK7, LRP4/6, and beta-catenin (CTNNB1). b Western blot of porcupine (PORCN), phosphorylated-AKT (p-AKT Ser
473), total AKT, and beta-actin (loading control), before and after treatment of three TNBC cell lines with buparlisib. The western blot shows
signiﬁcant induction of PORCN protein after treatment with buparlisib across all three cell lines
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231 saw signiﬁcant increases at their corresponding IC50s (p-value
of 0.013 and 0.0072, respectively) (Supplementary Table 3).
Dual pathway inhibition with buparlisib + WNT974 demonstrates
in vitro synergism
We then went on to test the effect of the combination in reducing
TNBC cell viability in vitro. We tested the combination of buparlisib
and WNT974 by treating TNBC cell lines MDA-MB-231, Hs578T,
and HCC70, with increasing concentrations of each drug. As seen
in the cascade plots, all three cell lines were observed to have a
signiﬁcant reduction in cell viability when the treatment was used
in combination (Fig. 3a–c). Using the Chou–Talalay method, we
observed for MDA-MB-231 and Hs578T, a ~50% reduction in cell
viability at 100 nM concentration of each drug that was highly
synergistic (combination index = 0.33 and 0.36, respectively).27 For
HCC70, we observed an additive effect that was more resistant to
the combination with an IC50 of 1 μM.
In vivo pharmacokinetics and pharmacodynamics (PD) of
buparlisib + WNT974
In the next step of further developing this combination, we
performed an in vivo pharmacokinetic (PK) experiment to assess
any potential drug–drug interactions. For PK, 45 NOD-scid
IL2Rgamma-null (NSG) mice were given a single dose of
buparlisib (n = 15), WNT974 (n = 15), or the combination (n = 15)
at pre-established concentrations of 30mg/kg and 3mg/kg,
respectively.26, 28 Plasma was drawn from three mice from each
group at 0.5, 1, 2, 6, and 24 h post-dosing. Buparlisib and WNT974
were quantiﬁed in the plasma using high-performance liquid
chromatography–mass spectrometry (HPLC-MS/MS). PK para-
meters were largely similar when comparing each drug alone or
in combination as demonstrated by similar Cmax concentrations,
area under the curves (AUCs), clearance rates (Cl/F) and volumes
of distribution (Vdss/F), suggesting the lack of a drug–drug
interaction (Supplementary Table 4).
To further assess preliminary efﬁcacy and target modulation, a
PD experiment was performed. For our PD study, we implanted
TMD-231 TNBC cells (a variant of the MDA-MB-231 cell line that
metastasizes to the lung) into the mammary fat pad of 24 NSG
mice (six mice per group: vehicle, buparlisib, LGK974, buparlisib +
WNT974). Tumors were allowed to grow for 29 days to an average
size of ~350 mm3. Mice were then dosed once per day with
buparlisib (30 mg/kg), WNT974 (3 mg/kg), or the combination for
7 days, with intermittent tumor measurements. After only 7 days
of treatment, we observed a ~40% decrease in tumor volume with
the combination, while tumors actually grew slightly in the face of
single agent therapy, again, giving further observations of synergy
(Fig. 4a). On the 7th day, the mice had plasma drawn, and then
euthanized and the tumor removed. Measurement of buparlisib
and WNT974 concentrations in tumor tissue conﬁrmed that these
agents were reaching the tumor (Fig. 4b). To assess molecular
target modulation, RNA and protein was isolated from each of the
tumors in our PD study and biomarker analysis was performed.
Inhibition of phospho-AKT, a marker for the activity of buparlisib,
was observed in the buparlisib and buparlisib +WNT974 samples,
Fig. 3 In vitro efﬁcacy of buparlisib and WNT974 across three TNBC cell lines. Buparlisib and WNT974 were dosed at increasing concentrations
(x and y-axes), and the percentage of cell viability was measured (z-axis) for cell lines: MDA-MB-231 (a), Hs578T (b) and HCC70 (c). Data is
displayed as a cascade plot. Using the Chou–Talalay method, we observed for MDA-MB-231 and Hs578T, a ~50% reduction in cell viability at
100 nM concentration of each drug that was highly synergistic (combination index= 0.33 and 0.36, respectively). For HCC70, we observed an
additive effect that was more resistant to the combination with an IC50 of 1 μM
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but not in the vehicle or the WNT974 alone samples. (Supple-
mentary Fig. 3a). Similarly, decreased AXIN2 RNA levels (a marker
of WNT974 activity) was observed in the WNT974 and combina-
tion treated tumors, but not the others (Supplementary Fig. 3b).
The TMD-231 cells used in our PD study have a known
propensity to metastasize to the lung.29 To assess the effect of the
combination therapy on the growth of lung metastases, lung
tissues from our PD study were stained and analyzed for
metastatic burden. When compared with the control group,
buparlisib and WNT974 as single agents displayed small but
non-signiﬁcant decreases in lung metastases (Fig. 4c). The
combination treatment, however, resulted in a signiﬁcant
Fig. 4 Pharmacodynamic study of buparlisib +WNT974 using cell line xenografts of the TNBC cell line, TMD231 (a MDA-MB-231 cell line variant
that metastasizes to the lung). a Graph of tumor volumes of NSG mice implanted with TMD-231 cells and treated with vehicle, buparlisib,
WNT974, or the combination. After 7 days of treatment, we observe a ~40% decrease in tumor volume. b Quantiﬁcation of drug in tumors
resected from mice treated in our PD study. Half of the tumors were resected at 1 h post the last dose, and the other half 7 h post the last dose.
Using Highperformance liquid chromatography-mass spectrometry (HPLC-MS/MS), buparlisib and WNT974 were quantiﬁed as nanograms of
drug per gram of tumor tissue (ng/g). Average values with standard deviation are presented. LOQ limit of quantitation c As TMD-231 cells have
a known propensity to metastasize to the lung, we assessed the effect of the combination therapy on the growth of lung metastases. When
compared with the control group, buparlisib and WNT974 as single agents displayed small but non-signiﬁcant decreases in lung metastases.
The combination treatment, however, resulted in a signiﬁcant decrease in lung metastatic burden compared to the control group (p= 0.0196)
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decrease in lung metastatic burden compared to the control
group (p = 0.0196).
Buparlisib +WNT974 demonstrates superior survival in TNBC PDX
bearing mice
In a ﬁnal efﬁcacy experiment, we tested the buparlisib + WNT974
combination in vivo against a TNBC patient-derived xenograft
(PDX). The PDX was selected from Jackson Laboratories based
upon its molecular proﬁle (http://tumor.informatics.jax.org/mtbwi/
pdxDetails.do?gene=null&variant=null&modelID=TM00091). This
tumor was BRCA1 mutated, and had an observed increase in
expression in AKT3 and PIK3CA, and a signiﬁcant decrease in
expression of PTEN, demonstrating an active PI3K/AKT pathway.
Forty mice were treated in four groups (n = 10 each): vehicle,
buparlisib, WNT974, and the combination of buparlisib +WNT974.
PDX tumors were ﬁrst grown to an average tumor size of 70–150
mm3, and then treated over the course of 28 days. At the end of
the experiment, 80% of mice treated with the combination
survived to the end of the study (Fig. 5). In comparison, only 40,
30, and 0% of mice survived treated with buparlisib, Vehicle, and
WNT974, respectively. Buparlisib is known to have toxicity in
humans (depression, anxiety, pneumonitis, and liver toxicity) that
may be exacerbated with the addition of WNT974 (whose most
common side effect is dysgeusia). To assess potential toxicity of
the combination, we measured the body weights of the mice
throughout the experiment. Body weights remained consistent
between the four treatment groups with a slight average increase
in body weight during the course of experiment (Supplementary
Fig. 4).
DISCUSSION
Combination targeted therapies hold signiﬁcant promise for the
treatment of metastatic cancer. Common clinical examples include
palbociclib + fulvestrant for metastatic estrogen-receptor-positive
breast cancer,30 and dabrafenib + trametinib31 and nivolumab +
ipilimumab32 for metastatic melanoma. In the present pre-clinical
study, we demonstrate that dual inhibition of the PI3K and Wnt
pathway is synergistic against TNBC. Furthermore, our data
suggests that the Wnt pathway is activated in a compensatory
fashion when TNBC cells are challenged with pan- PI3K inhibition.
The hyperactivation of the PI3K pathway is a characteristic seen in
many cancers.33 It is responsible for the regulation of cell survival,
cell cycle progression, and cellular growth.33 Of interest, the
majority of TNBCs have a genomic aberration in the PI3K/AKT
pathway, suggesting this pathway as a precision medicine target.
But single-agent PI3K inhibition alone may not be enough to illicit
meaningful clinical responses. In this study, we employed a
unique approach where the ﬁrst drug was chosen based on
genomic proﬁling (buparlisib; PI3K), and the second drug based
on the compensatory pathway (WNT974, porcupine/Wnt-path-
way). This approach is akin to a game of “whack-a-mole”, and
suggests a paradigm where hitting both pathways (genomically-
aberrant + compensatory) can induce drug synergy.
The compensatory WNT pathway observed in our study is well
known for its role in tissue development and cancer metastases.20
Of interest, both in silico bioinformatic prediction (based on a
large literature database) as well as next generation RNA-
sequencing of a TNBC cell line treated with buparlisib saw
induction of numerous Wnt pathway molecules including the
FZDs, WNT ligands, LRP4/6, PTK7, and porcupine (PORCN).
Porcupine induction at the protein level was subsequently
conﬁrmed in additional TNBC cell lines. Porcupine (the protein
target for WNT974), plays a role in the Wnt ligand maturation
process and whose O-acyltransferase activity is required for Wnt
ligand pamitoylation and secretion.21 WNT974 is currently being
tested in phase I clinical trials in a variety of tumor types
(clinicaltrials.gov). In an effort to support initiation of future clinical
trials of the buparlisib +WNT974 combination, we performed an
in vivo PK experiment to demonstrate, that at least in mice, we do
not observe a drug–drug interaction when buparlisib and WNT974
are co-administered. Further, in our PD experiment, we observed
that both drugs reach the tumor at concentrations that are
equivalent to when the drugs are administered individually. Lastly,
we demonstrate signiﬁcant efﬁcacy with the combination both in
a cell line xenograft and in an aggressive TNBC PDX model.
Crosstalk between the PI3K and Wnt pathways has been
previously reported. AKT is known to phosphorylate and inhibit
GSK3 leading to increased beta-catenin activity.34 More recent
data has demonstrated that colorectal tumors that have high
levels of beta-catenin are more resistant to PI3K/AKT inhibition.35
The exact mechanism of porcupine induction after pan-PI3K
inhibition is currently unknown, and warrants further
investigation.
In conclusion, we demonstrate a synergistic combination of
dual PI3K and Wnt pathway inhibition using buparlisib + WNT974
against triple-negative breast cancer. As drugs against both
pathways are currently in clinical trials as single agents, further
clinical exploration of dual pathway inhibition is well warranted.
Wnt pathway induction after PI3K inhibition provides a novel
mechanism of compensatory resistance to PI3K inhibitors that
may be applicable to other cancers with characteristic PI3K hyper-
activation.
METHODS
RNA sequencing and pathway analysis
Data from RNA-sequencing of 94 TNBCs compared to 20 normal breast
tissues microdissected for ductal epithelium, has been previously
described.18 Statistically signiﬁcant differentially expressed genes compar-
ing TNBC vs. normal breast tissues (as reported in Radovich et al.)18 were
imported into IPA for pathway, network, and upstream regulator analyses
(Qiagen, Redwood City, CA, USA). RNA-sequencing for the buparlisib
treated MDA-MB-231 cell line experiment was performed as follows. To
enrich for the non-ribosomal RNA transcriptome, RNA samples were ﬁrst
depleted of ribosomal RNA using the Low Input Ribominus Kit (Life
Technologies). ERCC spike-in controls (Pool 1) were introduced for all
samples (Life Technologies). RNA libraries were constructed using the Ion
Total RNA-Seq Kit for AB Library Builder System (Life Technologies) per
manufacturer’s instructions. Libraries were barcoded using the IonXpress
RNA-Seq Barcode 1–16 Kit (Life Technologies), and libraries were
quantiﬁed using the Agilent TapeStation 2200 along with the DNA D1K
Kit. Libraries were diluted to a concentration of 11 pM prior to templating
and emulsion polymerase chain reaction (PCR) using the Ion Template OT2
200 v2 kit along with Ion OneTouch 2 instrument (Life Technologies).
Templates were quantiﬁed using the IonSphere Quality Control Kit (Life
Fig. 5 NSG mice were implanted with a TNBC PDX and were treated
in four groups (n= 10 each): vehicle, buparlisib, WNT974, and the
combination of buparlisib +WNT974. At the end of the experiment,
80% of mice treated with the combination survived to the end of
the study. In comparison, only 40, 30, and 0% of mice survived
treated with buparlisib, vehicle, and WNT974, respectively
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Technologies). Samples were sequenced on an Ion Proton Next-Generation
Sequencer using the Ion Proton PI chip and the Ion PI Sequencing 200 v2
kit (Life Technologies). Samples were sequenced using two RNA-seq
libraries/samples per chip to an average of 30–40 million reads per sample.
Reads were mapped to the human genome (hg19) using the STAR
algorithm.36 Aligned BAM ﬁles were then imported into Partek Genomics
Suite. RPKM values were called in Partek using the NCBI Refseq database as
the gene model.
In vitro drug sensitivity in TNBC cell lines
Buparlisib (a pan-PI3K inhibitor) and WNT974 (a Wnt pathway inhibitor
formerly known as LGK974) were obtained under a Material Transfer
Agreement with Novartis (Basel, Switzerland). We assessed PI3K and Wnt
pathway drug sensitivity, and synergy on three TNBC cell lines; Hs578T,
HCC70, and MDA-MB-231. Cells were maintained either in Dulbecco's
modiﬁed eagle medium or Roswell Park Memorial Institute medium with
10% FBS, in humidiﬁed 5% CO2 incubators. 10,000 cells per well were
seeded in 96-well plates and were dosed with increasing log concentra-
tions (1 nM–100 μM) of buparlisib and WNT974 as single-agents and in
combination. Cells were treated in a 6 × 6 matrix such that each
combination of each dose was tested, with a cascade plot generated
from the data. Cell viability was assayed using the Celltiter-Fluor kit
(Promega, Madison, Wisconsin) with ﬂuorescence measured using a
Synergy 4 microplate reader (BioTek, Winooski, Vermont). The
Chou–Talalay method was used to calculate a Combination Index (CI)
score to determine synergism.37
In vivo pharmacokinetics and PD
For PKstudies, NSG mice were obtained from the In Vivo Therapeutics (IVT)
Core at the Indiana University School of Medicine and given a single dose
of buparlisib, WNT974, or the combination at pre-established concentra-
tions of 30mg/kg and 3mg/kg respectively.26, 28 This experiment
employed 45 NSG mice (n = 15 for each group). Plasma was drawn from
three mice from each group at 0.5, 1, 2, 6, and 24 h post dosage. Buparlisib
and WNT974 were quantiﬁed using HPLC-MS/MS. PK parameters for
buparlisib and WNT974 including AUC, area under the moment curve
(AUMC), and half-life (t½) were estimated using noncompartmental
methods with Excel®. The maximum plasma concentration (Cmax) and time
of Cmax (tmax) were obtained from the data. The AUC from zero to inﬁnity
(AUC0–∞) was estimated from the AUC0–t (time zero to the last quantiﬁable
concentration Clast) and the AUC from Clast to inﬁnity, Clast/kel, where kel is
the rate constant of elimination. The AUMC0–∞ was estimated by an
analogous manner. The clearance (Cl/F, where F = bioavailability) of
buparlisib and WNT974 were calculated from the dose and AUC0–∞. The
apparent volume of distribution (Vdss/F) was estimated by the following
equation: (dosage/AUC0–∞) × (AUMC0–∞/AUC0–∞). The single-agent
PKparameters were compared to the drug combination parameters to
determine whether a drug–drug interaction exists. For our pharmacody-
namic studies, NSG mice were implanted with TMD-231 TNBC cells into the
mammary fat pad of 24 NSG mice (six mice per group: vehicle, buparlisib,
WNT974, buparlisib +WNT974). The TMD-231 cell line is a variant of the
MDA-MB-231 cell line that metastasizes to the lung. Tumors were allowed
to grow to an average size of approximately 350mm3 prior to dosing. To
validate compound-mediated modulation of the PI3K/mTOR and Wnt
signaling pathways, mice were dosed once a day with vehicle, buparlisib
(30mg/kg), WNT974 (3 mg/kg), or the combination for 7 days. On the 7th
day, the mice had plasma drawn, were euthanized, and the tumors were
removed. To capture early and late PD effects, half the mice in each group
were euthanized with tumors removed at 1 h after the last dose and the
other half at 7 h. The drugs in the plasma and tumor tissue were quantiﬁed
as described previously. All murine studies were approved by the Indiana
University Institutional Animal Care and Use Committee (IACUC).
Western blotting and qPCR validation
Target modulation was assessed using qPCR for Axin2 (a marker of
WNT974), and western blot for porcupine and phospho-Akt Ser 473 (a
marker of buparlisib activity). qPCR was performed using Taqman assays
(Life Technologies). Protein was isolated after 48 h of treatment in
biological triplicates using radioimmunoprecipitation assay buffer and
quantiﬁed with bicinchoninic acid assay (Thermo Fisher). Protein was run
on bis-tris gels (Life Technologies) and transferred to polyvinylidene
ﬂuoride membrane. Primary pAKT-Ser 473 antibody (Cell Signaling
Technology, Beverly, Massachusetts), β-actin (Cell Signaling Technology),
and PORCN (Abcam, Cambridge, England) was incubated overnight with
subsequent 1-hour incubation with horseradish peroxidase-conjugate
secondary antibody. Staining was performed using a chemiluminescent
substrate (ThermoFisher). Imaging was performed using an LAS-4000
Luminescent Image Analyzer (Fujiﬁlm, Tokyo, Japan). Quantiﬁcation of
blots was performed using ImageJ (NIH) and statistical analysis using
GraphPad.
Quantiﬁcation of lung metastases
Lungs were extracted, ﬁxed in 10% formalin, and processed in parafﬁn.
Five-micrometer sections were H&E stained, deparafﬁnized, blocked, and
stained using primary anti-human Ki67 antibody (DAKO, Carpinteria,
California). The Aperio whole slide digital imaging system was used for
imaging (Leica, Wetzlar, Germany). Using the Aperio ScanScope CS, ×20
images were taken at scan times ranging from 1.5 to 2.25min. The total
nuclear labeling index (Ki67) was generated using the Aperio ImageScope
standard positive pixel algorithm. The Image Analysis software was used to
calculate the percent of positive pixels (brown staining) in one large cross
section from each lung.
TNBC PDX
NSG mice were trochar implanted in the right hind ﬂank with a passage
1–4, 5 mm3 TNBC PDX (ID: BR0901) at The Jackson Laboratory (The Jackson
Laboratory, Bar Harbor, Maine). Forty TNBC PDX implanted mice were used
(ten mice per group: vehicle, buparlisib (30 mg/kg), WNT974 (3 mg/kg), and
buparlisib +WNT974). Tumors were grown to an average of 70–150mm3
and mice averaged 22.5 g body weight. Mice were dosed once-a-day for a
maximum of 28 days. Tumor measurements were made two times a week.
Mice whose tumors reached a size of 1500mm3 were euthanized per
IACUC protocol. To assess toxicity, body weights were measured at the
time of tumor measurements.
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